2020
Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study
Mahajan S, Srinivasan R, Redlich CA, Huston SK, Anastasio KM, Cashman L, Massey DS, Dugan A, Witters D, Marlar J, Li SX, Lin Z, Hodge D, Chattopadhyay M, Adams MD, Lee C, Rao LV, Stewart C, Kuppusamy K, Ko AI, Krumholz HM. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. The American Journal Of Medicine 2020, 134: 526-534.e11. PMID: 33130124, PMCID: PMC7598362, DOI: 10.1016/j.amjmed.2020.09.024.Peer-Reviewed Original ResearchConceptsSARS-CoV-2-specific IgG antibodiesWeighted seroprevalenceIgG antibodiesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodiesSARS-CoV-2-specific antibodiesConnecticut residentsSelf-reported adherenceImmunoglobulin G antibodiesSARS-CoV-2Symptomatic illnessSerology testingSeroprevalence studyG antibodiesPrevalence studyGeneral populationPercentage of peopleSeroprevalenceLack antibodiesMajority of respondentsAntibodiesHispanic subpopulationsConvenience sampleHispanic populationCOVID-19Risk mitigation behaviors
2001
The Connecticut Cardiovascular Consortium: a unique, state-wide research collaboration to advance clinical outcomes in patients with heart disease.
Boden WE, McKay RG, Cabin HS, Radford MJ, Krumholz HM, Zaret BL, Garner L, Bull MB, Fisherkeller M, Kosinski EJ, Krauthamer MJ, Maljanian R, McDowell AV, Sands MJ, Schwartz KV, Seltzer JP, Hager JD. The Connecticut Cardiovascular Consortium: a unique, state-wide research collaboration to advance clinical outcomes in patients with heart disease. Connecticut Medicine 2001, 65: 597-604. PMID: 11702518.Peer-Reviewed Original ResearchConceptsST-segment elevation acute myocardial infarctionPercutaneous coronary interventionClinical outcomesSegment elevation acute myocardial infarctionConnecticut residentsPatient careElevation acute myocardial infarctionUltimate clinical impactHealth care delivery modelsAcute myocardial infarctionCurrent health care policiesClinical outcome assessmentHealth care providersGood clinical practiceHealth care accessDifferent treatment patternsEvidence-based medicineHealth care policyMechanical reperfusionMechanical revascularizationPCI capabilityCoronary interventionFibrinolytic therapyTreatment patternsMyocardial infarction